AU2018201011A1 - Methods for treating HCV - Google Patents

Methods for treating HCV Download PDF

Info

Publication number
AU2018201011A1
AU2018201011A1 AU2018201011A AU2018201011A AU2018201011A1 AU 2018201011 A1 AU2018201011 A1 AU 2018201011A1 AU 2018201011 A AU2018201011 A AU 2018201011A AU 2018201011 A AU2018201011 A AU 2018201011A AU 2018201011 A1 AU2018201011 A1 AU 2018201011A1
Authority
AU
Australia
Prior art keywords
weeks
hcv
patient
daas
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2018201011A
Other languages
English (en)
Inventor
Walid M. Awni
Barry M. Bernstein
Andrew L. Campbell
Sandeep Dutta
Chih-Wei Lin
Wei Liu
Rajeev M. Menon
Sven MENSING
Thomas J. PODSADECKI
Tianli WANG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie Inc
Original Assignee
AbbVie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/431,906 external-priority patent/US11484534B2/en
Application filed by AbbVie Inc filed Critical AbbVie Inc
Publication of AU2018201011A1 publication Critical patent/AU2018201011A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2018201011A 2017-02-14 2018-02-12 Methods for treating HCV Abandoned AU2018201011A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15/431,906 2017-02-14
US15/431,906 US11484534B2 (en) 2013-03-14 2017-02-14 Methods for treating HCV

Publications (1)

Publication Number Publication Date
AU2018201011A1 true AU2018201011A1 (en) 2018-08-30

Family

ID=61192811

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018201011A Abandoned AU2018201011A1 (en) 2017-02-14 2018-02-12 Methods for treating HCV

Country Status (7)

Country Link
EP (1) EP3360555A1 (cg-RX-API-DMAC10.html)
JP (1) JP2018131439A (cg-RX-API-DMAC10.html)
CN (1) CN108421029A (cg-RX-API-DMAC10.html)
AU (1) AU2018201011A1 (cg-RX-API-DMAC10.html)
BR (1) BR102018002956A2 (cg-RX-API-DMAC10.html)
CA (1) CA2994496A1 (cg-RX-API-DMAC10.html)
MX (1) MX2018001905A (cg-RX-API-DMAC10.html)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20060118532A (ko) * 2003-12-11 2006-11-23 쉐링 코포레이션 Ｃ형 간염 바이러스 ｎｓ３／ｎｓ４ａ 세린 프로테아제의억제제
US9394279B2 (en) 2009-06-11 2016-07-19 Abbvie Inc. Anti-viral compounds
TWI523658B (zh) 2010-09-21 2016-03-01 安塔製藥公司 巨環脯胺酸衍生之ｈｃｖ絲胺酸蛋白酶抑制劑
CN104023726A (zh) 2011-10-21 2014-09-03 艾伯维公司 用于治疗hcv的一种或多种daa的联合治疗(例如，与abt-072或abt-333)
DE112012003510T5 (de) * 2011-10-21 2015-03-19 Abbvie Inc. Verfahren zur Behandlung von HCV umfassend mindestens zwei direkt wirkende antivirale Wirkstoffe, Ribavirin aber nicht Interferon
WO2014152514A1 (en) * 2013-03-14 2014-09-25 Abbvie Inc. Combination of two antivirals for treating hepatitis c
EP3318258B1 (en) * 2013-03-14 2020-05-13 AbbVie Inc. Combination of direct acting antiviral agents and ribavirin for treating hcv patients
BR112016022976A8 (pt) * 2014-04-02 2021-07-20 Abbvie Inc métodos para o tratamento de hcv
US20180177779A1 (en) * 2015-07-08 2018-06-28 Abbvie Inc. Methods for Treating HCV

Also Published As

Publication number Publication date
JP2018131439A (ja) 2018-08-23
CN108421029A (zh) 2018-08-21
EP3360555A1 (en) 2018-08-15
MX2018001905A (es) 2018-11-09
CA2994496A1 (en) 2018-08-14
BR102018002956A2 (pt) 2018-10-30

Similar Documents

Publication Publication Date Title
AU2016202823B2 (en) Combination of two antivirals for treating Hepatitis C
AU2018202581B2 (en) Combination of direct acting antiviral agents and ribavirin for treating HCV patients
US20240232171A1 (en) Methods for Treating HCV
US20170360783A1 (en) Methods for Treating HCV
US20200368229A9 (en) Methods for Treating HCV
US11484534B2 (en) Methods for treating HCV
US20250057837A1 (en) Methods for Treating HCV
US20240082245A1 (en) Methods for Treating HCV
US20230385268A1 (en) Methods for Treating HCV
EP3360555A1 (en) Methods for treating hcv
US20200222397A1 (en) Methods for Treating HCV
US20200330460A1 (en) Methods for Treating HCV
HK1259694A1 (en) Methods for treating hcv
HK40004326A (en) Methods for treating hcv
JP2020536909A (ja) Ｈｃｖを処置するための方法

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted